This Administrative Core (Core A) will provide the necessary scientific, organizational, and fiscal oversight of the Consortium for Development of Immunotherapeutics Against Viral Hemorrhagic Fevers. This consortium includes multiple investigators and a vast array of antibodies with in vitro or in vivo efficacy against the filoviruses and arenaviruses. An essential feature ofthe consortium is coordination of projects and studies on these antibodies, so that effort is not unduly duplicated, the separate multidisciplinary analyses integrate effectively and seamlessly, and the group achieves maximum synergy. The Administrative Core will develop and implement a management plan to ensure the success of this program. This Core will continuously monitor the scientific progress of each component of the program and ensure that results, the meaning of the results, and next steps are effectively communicated to the rest of the group at each stage. This Core will also facilitate communications with the NIH, the larger research community, and our external advisors so that these comprehensive studies are definitive and defined by consensus in the fields, and so that the resulting products can be effectively translated toward clinical use. The Core will manage financial resources and ensure that the select agent, vertebrate animal, human subject, and intellectual property issues are respected. The Core will also initiate all external collaborations and oversee invitation, selection, and progress of supplemental research activities as directed by the NIH.
This Core will provide the necessary administrative, organizational and fiscal oversight to ensure that critical antibody therapeutics against viral hemorrhagic fevers are translated toward patient use.
|Holtsberg, Frederick W; Shulenin, Sergey; Vu, Hong et al. (2016) Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses. J Virol 90:266-78|
|Wec, Anna Z; Nyakatura, Elisabeth K; Herbert, Andrew S et al. (2016) A "Trojan horse" bispecific antibody strategy for broad protection against ebolaviruses. Science :|
|Pallesen, Jesper; Murin, Charles D; de Val, Natalia et al. (2016) Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nat Microbiol 1:16128|
|Frei, Julia C; Nyakatura, Elisabeth K; Zak, Samantha E et al. (2016) Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses. Sci Rep 6:19193|
|Natesan, Mohan; Jensen, Stig M; Keasey, Sarah L et al. (2016) Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses. Clin Vaccine Immunol 23:717-24|
|Qiu, Xiangguo; Audet, Jonathan; Lv, Ming et al. (2016) Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Sci Transl Med 8:329ra33|
|Bornholdt, Zachary A; Turner, Hannah L; Murin, Charles D et al. (2016) Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science 351:1078-83|
|Goba, Augustine; Khan, S Humarr; Fonnie, Mbalu et al. (2016) An Outbreak of Ebola Virus Disease in the Lassa Fever Zone. J Infect Dis 214:S110-S121|
|Robinson, James E; Hastie, Kathryn M; Cross, Robert W et al. (2016) Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat Commun 7:11544|
|Zeitlin, Larry; Whaley, Kevin J; Olinger, Gene G et al. (2016) Antibody therapeutics for Ebola virus disease. Curr Opin Virol 17:45-9|
Showing the most recent 10 out of 27 publications